General Updates

September 18, 2026 To To BSE Limited National Stock Exchange of India Limited 25th Floor, P. J. Towers, Exchange Plaza, Bandra Kurla Complex Dalal Street, Mumbai - 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 543064 Scrip Symbol: COHANCE Dear Sir/Madam, Sub: Investment in Compulsorily Convertible Preferred Stock of NJ Bio Inc., USA This is in continuation of our letter dated December 2, 2025, wherein the Company had informed regarding the approval of its Board of Directors for fund infusion by way of investment in Compulsorily Convertible Preferred Stock ("CCPS") of NJ Bio Inc., USA ("NJ Bio"), a subsidiary of the Company, up to an amount of USD 10 million. We hereby inform that the Company has remitted the aggregate consideration of USD 10 million towards subscription of new CCPS of NJ Bio. The details required under SEBI Circular No. SEBI/HO/49/14/14(7)2025-CFD- POD2/I/3762/2026 dated January 30, 2026 are enclosed herewith as Annexure A. Kindly take the above on record. Thanking you. Yours faithfully, For Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) Sisir K Mishra Company Secretary & Compliance Officer Encl: As above. Annexure-A Investment in Compulsorily Convertible Preferred Stock of NJ Bio Inc Sl Particulars Details a. Name of the target entity, details in Name of the Target: brief such as size, turnover etc. NJ Bio, Inc (NJ Bio) having its registered office at 251 Little Falls Drive, Wilmington, New Castle County, Delaware, 19808 and corporate office at 350 Carter Road, Princeton, NJ 08540. Details of the Target: NJ Bio is an Antibody Drug Conjugate (“ADC”) focused Contract Research, Development, and Manufacturing Organization (“CRDMO”) and one of the leading global players with end-to-end capabilities across payload-linker synthesis, bioconjugation and analytical services, providing customized ADC solutions that accelerate customers’ discovery and development. Turnover: • CY2023: USD 20.6 million • CY2024: USD 32.6 million • CY2025: USD 23.5 million b. Whether the acquisition would fall The transaction would fall within related party within related party transaction(s) and transaction, as NJ Bio is a subsidiary of the Company. whether the promoter/ promoter The promoter/ promoter group/ group companies of the group/ group companies have any Company do not have any direct interest in NJ Bio, interest in the entity being acquired? If other than through the Company as aforesaid. The yes, nature of interest and details transaction is at arm’s length. thereof and whether the same is done at “arm’s length” c. Industry to which the entity being Pharmaceutical / Chemical Compounds CRDMO acquired belongs d. Objects and impact of acquisition Cohance, along with its subsidiaries/affiliates, is (including but not limited to, engaged in the contract development, manufacture and disclosure of reasons for acquisition of sale of drug products and other allied activities. NJ Bio target entity, if its business is outside is amongst the few CRDMOs in the high growth ADC the main line of business of the listed and broader ‘XDC’ (other conjugation-based therapies) entity) space. This investment reinforces Cohance’s commitment to the ADC space and will support NJ Bio’s growth initiatives including capex . e. Brief details of any governmental or The transaction will be in accordance with the regulatory approvals required for the applicable provisions of the FEMA (Overseas acquisition; Investment) Regulations, 2022 read with the rules and circulars made thereunder. Further, the Company will make applicable regulatory filings with the relevant authorities, as may be required under applicable laws. f. Indicative time period for completion The Company has remitted the aggregate of the acquisition; consideration amount and expects to complete the transaction before end of September 2026. g. Consideration - whether cash Cash consideration (through internal accruals) for consideration or share swap or any subscription to new Compulsorily Convertible other form and details of the same; Preference Stocks (“CCPS”) of NJ Bio. h. Cost of acquisition and/or the price at The aggregate consideration is USD 10 Million for the which the shares are acquired; primary subscription of 188,680 CCPS of NJ Bio at USD 53.00 per CCPS. i. Percentage of shareholding / control Upon completion of the transaction, the Company will acquired and / or number of shares hold 188,680 CCPS of NJ Bio which are convertible to acquired equity shares of NJ Bio after 3 years in accordance with the terms of the definitive agreements. j. Brief background about the entity Brief background and line of business: acquired in terms of products/line of NJ Bio is an ADC / ‘XDC’ focused CRDMO and one of business acquired, date of the leading global players with end-to-end capabilities incorporation, history of last 3 years across payload-linker synthesis, bioconjugation and turnover, country in which the ADCs characterization, providing customized ADC acquired entity has presence and any solutions that accelerate customers’ discovery and other significant information (in development. brief); Date of Incorporation: NJ Bio, Inc. (formerly known as NJ Biopharmaceuticals LLC), was incorporated as a limited liability company under applicable laws on 23 October 2017 in Bristol, Pennsylvania, USA, and was subsequently converted to an incorporated corporation, in the name of NJ Bio, Inc., on 01 August 2022 in Delaware, USA. Turnover of last 3 years: • CY2023: USD 20.6 million • CY2024: USD 32.6 million • CY2025: USD 23.5 million Country in which the entity has presence: Other than USA, NJ Bio has business operations in India through a subsidiary entity, NJBIO India Pharmaceutical Private Limited.